Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Revenue: 2010-2024

Historic Revenue for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $20,000.

  • Altimmune's Revenue changed negligibly% to $5,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $20,000, marking a year-over-year decrease of 61.54%. This contributed to the annual value of $20,000 for FY2024, which is 95.31% down from last year.
  • According to the latest figures from FY2024, Altimmune's Revenue is $20,000, which was down 95.31% from $426,000 recorded in FY2023.
  • Over the past 5 years, Altimmune's Revenue peaked at $8.2 million during FY2020, and registered a low of $20,000 during FY2024.
  • Moreover, its 3-year median value for Revenue was $68,000 (2022), whereas its average is $171,333.
  • As far as peak fluctuations go, Altimmune's Revenue crashed by 98.46% in 2022, and later spiked by 526.47% in 2023.
  • Yearly analysis of 5 years shows Altimmune's Revenue stood at $8.2 million in 2020, then slumped by 46.12% to $4.4 million in 2021, then tumbled by 98.46% to $68,000 in 2022, then surged by 526.47% to $426,000 in 2023, then plummeted by 95.31% to $20,000 in 2024.